Evidence map›Paper›PMID 33937571›Full record

ArticleGlobal health & medicine2021

Consistency of the results of rapid serological tests for SARS-CoV-2 among healthcare workers in a large national hospital in Tokyo, Japan.

Shohei Yamamoto, Akihito Tanaka, Shinji Kobayashi, Yusuke Oshiro, Mitsuru Ozeki, Kenji Maeda, Kouki Matsuda, Kengo Miyo, Tetsuya Mizoue, Wataru Sugiura and 3 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Global health & medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Shohei YamamotoDepartment of Epidemiology and Prevention, Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan.
Akihito TanakaDepartment of Laboratory Testing, Center Hospital of the National Center for Global Health and Medicine, Tokyo, Japan.
Shinji KobayashiDepartment of Laboratory Testing, Center Hospital of the National Center for Global Health and Medicine, Tokyo, Japan.
Yusuke OshiroDepartment of Laboratory Testing, Center Hospital of the National Center for Global Health and Medicine, Tokyo, Japan.
Mitsuru OzekiDepartment of Laboratory Testing, Center Hospital of the National Center for Global Health and Medicine, Tokyo, Japan.
Kenji MaedaDepartment of Refractory Viral Infection, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan.
Kouki MatsudaDepartment of Refractory Viral Infection, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan.
Kengo MiyoCenter of Medical Informatics Intelligence, National Center for Global Health and Medicine, Tokyo, Japan.
Tetsuya MizoueDepartment of Epidemiology and Prevention, Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan.
Wataru SugiuraCenter for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan.
Hiroaki MitsuyaResearch Institute, National Center for Global Health and Medicine, Tokyo, Japan.
Haruhito SugiyamaCenter Hospital of the National Center for Global Health and Medicine, Tokyo, Japan.
Norio OhmagariDisease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
National Center for Global Health and Medicine · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We assessed the consistency of seropositive results of three rapid immunoassays (Kits A, B, and C) for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) compared to highly accurate serological tests (Abbott and Roche) among healthcare workers in a hospital in Tokyo. The seroprevalence of SARS-CoV-2 immunoglobulin G was 0.41%, 2.36%, and 0.08% using Kits A, B, and C, respectively. Of the 51 samples that were seropositive on any rapid test, all were seronegative on both the Abbott and the Roche assays. Given that the seroprevalence of SARS-CoV-2 immunoglobulin G varied widely according to the choice of rapid test and the rapid test results were inconsistent with the results of highly accurate tests, the diagnostic accuracy of rapid serological tests for SARS-CoV-2 should be assessed before introducing these tests for point-of-care testing or surveillance.

Indexed as

COVID-19immunoassaySARS-CoV-2serological testsseroprevalence

Identifiers

PMID33937571
PMCPMC8071682
OpenAlexW3140722227

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.